Literature DB >> 17571294

The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.

Helene J De Rosa1, Helen M Baldan, Iguatemy L Brunetti, Valdecir F Ximenes, Rosângela G P Machado.   

Abstract

Hepatotoxicity is the main concern during tuberculosis chemotherapy with the first-line drugs isoniazid (INH), rifampicin (RMP) and pyrazinamide (PYR). Since these hepatotoxic events have been associated with INH metabolites, the study aimed to measure the area under curve (AUC) parameter for INH and its metabolites acetylisoniazid (AcINH), hydrazine (Hz) and acetylhydrazine (AcHz), when groups of rats were pre-treated for 21 days with INH alone or in combination with RMP and/or PYR, in the following amounts per kg body weight: INH 100 mg; INH 100 mg + RMP 100 mg; INH 100 mg + PYR 350 mg; INH 100 mg + PYR 350 mg + RMP 100 mg. It was found that co-administration of RMP, PYR and RMP + PYR caused a significant decrease in the AUC for INH. Co-administration of PYR was the only treatment that caused a significant increase in the AUC for Hz and a decrease in the AUC for its acetylated product AcHz. The AUC for AcINH was not significantly altered in any experimental group. In conclusion, the increased metabolism of INH in all the drug combinations and the significantly higher production of Hz in the group INH + PYR might be linked with exacerbated hepatotoxic effects of these drug associations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571294     DOI: 10.1002/bdd.557

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  4 in total

1.  Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence.

Authors:  Saif Khan; Raju K Mandal; Abdulbaset Mohamed Elasbali; Sajad A Dar; Arshad Jawed; Mohd Wahid; Harishankar Mahto; Mohtashim Lohani; Bhartendu Nath Mishra; Naseem Akhter; Ali A Rabaan; Shafiul Haque
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840

2.  Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort.

Authors:  Shaowen Tang; Xiaozhen Lv; Yuan Zhang; Shanshan Wu; Zhirong Yang; Yinyin Xia; Dehua Tu; Peiyuan Deng; Yu Ma; Dafang Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

3.  The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Authors:  Yang Xiang; Long Ma; Weidong Wu; Wei Liu; Yongguang Li; Xia Zhu; Qian Wang; Jinfeng Ma; Mingqin Cao; Qian Wang; Xuemei Yao; Lei Yang; Atikaimu Wubuli; Corinne Merle; Paul Milligan; Ying Mao; Jiayi Gu; Xiumei Xin
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

4.  Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin.

Authors:  Sayed Ab Reshad Ghafouri; Alexander Brun; Rohit Bhalla; Craig Margulies; Kevin Skole
Journal:  Case Rep Oncol Med       Date:  2018-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.